0000000000306710

AUTHOR

Salvatore Del Prete

showing 4 related works from this author

Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.

2011

Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC…

OncologyAdultMaleCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaAntineoplastic AgentsBreast NeoplasmsDrug resistanceAntibodies Monoclonal HumanizedMetastasisBreast Neoplasms MaleAntineoplastic AgentCohort StudiesBreast cancerRetrospective StudieTrastuzumabInternal medicinemedicineHumansskin and connective tissue diseasesMetastatic breast cancer; Smoking; Trastuzumab; Adult; Aged; Aged 80 and over; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms Male; Cohort Studies; Drug Resistance Neoplasm; Female; Humans; Male; Middle Aged; Retrospective Studies; Smoking; Cancer Research; OncologyneoplasmsAgedRetrospective StudiesGynecologyAged 80 and overbusiness.industrySmokingCancerAntibodies MonoclonalRetrospective cohort studyGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerOncologyDrug Resistance Neoplasmtrastuzumab smoking metastatic breast cancerFemalemetastatic breast cancerBreast diseaseCohort StudiebusinessBreast NeoplasmHumanmedicine.drug
researchProduct

Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer

2005

Abstract BACKGROUND AND AIMS: oxaliplatin in combination with folinic acid (FA) and infusional 5-fluorouracil (5-FU) has shown significant anti-tumor activity in gastric cancer patients (FOLFOX). Previous studies have shown that gemcitabine (GEM), a new fluorinated anti-metabolite, enhances the individual anti-tumor activity of either 5-FU or oxaliplatin. We have therefore designed a multi-center phase II trial in order to test a novel GEM+FOLFOX-4 regimen in patients with metastatic gastric cancer. METHODS: we enrolled 36 patients, 28 males and 8 females, with an average age of 64.4 years (range 37-78), who received bi-weekly treatment with GEM (1,000 mg/m2 on day 1), levo-FA (100 mg/m2 on…

AdultMaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsGastrointestinal Diseasesmedicine.drug_classfolinic acidmedicine.medical_treatmentLeucovorinAdenocarcinomaToxicologyDeoxycytidineAntimetaboliteGastroenterologyFolinic acidFOLFOXStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans5-fluorouracilPharmacology (medical)Infusions IntravenousAgedNeoplasm StagingPharmacologyChemotherapybusiness.industrygastric canceroxaliplatingemcitabineMiddle AgedHematologic DiseasesGemcitabineSurgeryOxaliplatinSurvival RateRegimenOncologyFluorouracilFemaleNeurotoxicity SyndromesFluorouracilbusinessmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicente…

2006

This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as third- or fourth-line therapy in a retrospective series of patients with metastatic colorectal cancer refractory to oxaliplatin and irinotecan. Patients and Methods: Most patients (90%) had been previously treated with adjuvant 5-fluorouracil/leucovorin, and all had received oxaliplatin-based regimens before receiving irinotecan- based second-line treatment. Sixty patients with irinotecan-refractory colorectal cancer received a regimen comprising weekly irinotecan 120 mg/m 2 as a 1-hour intravenous infusion and cetuximab 400 mg/m 2 infused over 2 hours as the initial dose and 250 mg/m 2 infus…

AdultMaleOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSettore MED/06 - Oncologia MedicaColorectal cancermedicine.medical_treatmentCetuximabAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisSurvival analysisAgedAged 80 and overChemotherapyCetuximabPerformance statusbusiness.industryGastroenterologyAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesOxaliplatinErbB ReceptorsIrinotecanSettore MED/18 - Chirurgia GeneraleRegimenOncologyCamptothecinFemaleEpidermal growth factor receptor Oxaliplatin Vascular endothelial growth factorColorectal Neoplasmsbusinessmedicine.drugClinical Colorectal Cancer
researchProduct

Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib.

2010

Abstract Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients. Materials and Methods. All patients received 800 mg daily of sorafenib until progression or unacceptable toxicities. We retrospectively analyzed the incidence of rash and hand–foot skin reactions (HFSR) during the first month of treatment, comparing tumor control (partial response …

MaleCancer ResearchPyridinesSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologySkin Toxicity Hepatocellular CarcinomaSorafenib.Aged 80 and overintegumentary systemIncidence (epidemiology)BenzenesulfonatesLiver NeoplasmsMiddle AgedSorafenibRashhumanitiesOncologyHepatocellular carcinomaToxicityDisease ProgressionFemaleDrug Eruptionsmedicine.symptommedicine.drugAdultNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsInternal medicinemedicineCarcinomaHumansneoplasmsSurvival analysisAgedRetrospective StudiesSurrogate endpointbusiness.industryPhenylurea CompoundsExanthemamedicine.diseaseSurvival Analysisdigestive system diseasesSurgerybody regionsMultivariate AnalysisHepatobiliarybusiness
researchProduct